Atopic Dermatitis Digital Highlights - Podcasts
Faculty Interview Podcasts

Faculty Interview Podcasts

Atopic Dermatitis Therapy 

Atopic Dermatitis Therapy 

Lawrence Schachner, MD, discusses recent developments in the pediatric atopic dermatitis treatment landscape, including:

  • Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?
  • Dupilumab is currently approved for patients with atopic dermatitis aged 6 years and older. Do you foresee dupilumab being approved for even younger patients in the near future?
  • How do emerging JAK inhibitors fit into the existing treatment landscape for pediatric patients with atopic dermatitis?

Podcast also available on:

Pediatric Skin of Color Symposium: Atopic Dermatitis 

Pediatric Skin of Color Symposium: Atopic Dermatitis 

Latanya Benjamin, MD, shares clinical pearls about the management of atopic dermatitis in pediatric patients with skin of color, including:

  • Can you tell us about the number of emerging therapies for treatment of AD in pediatric patients and how this will change the treatment landscape?
  • What is your personal approach to treating AD in pediatric patients with skin of color?
  • Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?

Podcast also available on:

Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis

Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis

Linda Stein Gold, MD, Chair of the CME Symposium "Clinical Update: Novel Agents for the Long-Term Management of Moderate-to-Severe Atopic Dermatitis" at SBS 2021, leads a panel discussion with Peter Lio, MD and Andrew Alexis, MD, to share clinical pearls and key takeaways about the management of atopic dermatitis.

Podcast also available on:

Evolving Paradigms in Atopic Dermatitis

Evolving Paradigms in Atopic Dermatitis

Fernanda Schmidt, MD shares some clinical pearls about the evolving paradigms in AD, including:

  • What are the inside-out and outside-in mechanisms of AD?
  • Is there a difference between these mechanisms across the age spectrum – from children to adults?
  • Can we halt the atopic march by repairing the skin, or is it more than “skin deep”?

Podcast also available on:

Perspectives on emerging AD therapies

Perspectives on emerging AD therapies

Leon Kircik, MD discusses the potential role of emerging AD treatments, including:

  • Why has atopic dermatitis lagged behind compared to psoriasis in terms of approved targeted treatments?
  • What are some of the most promising therapies that will likely be part of the AD treatment table in the near future?
  • Do you foresee that they will be also approved for pediatric AD, or only for the adult population?
  • In terms of assessing disease severity, how practical are the scales used in clinical trials? Should we put more emphasis on patient-reported outcomes?

Podcast also available on:

Pearls on integrating newer AD treatments

Pearls on integrating newer AD treatments

Lawrence Schachner, MD discusses clinical pearls on the diagnosis and treatment of pediatric AD, including:

  • How do we make sure that we correctly diagnose atopic dermatitis? What are some clinical pearls you can share for our audience?
  • Since now dupilumab is approved for children with atopic dermatitis, what is its role and where would it fit into the “Schachner ladder”?
  • How do crisaborole and dupilumab fit into the long-term care of AD? For how long should they be used?

Podcast also available on:

The promise of JAK inhibitors in AD

The promise of JAK inhibitors in AD

Neal Bhatia, MD discusses the potential role of JAKis in AD, including:

  • What changes would JAKis bring to the treatment of AD in the near future?
  • What are some JAKis currently under clinical development for AD?
  • Do you foresee that JAKis will play a role in both adult and pediatric AD?
  • Where do you think they will fit in with the other recently-approved treatments for AD, or overall in the treatment regimen?
  • What are the long-term implications for dermatology practice?

Podcast also available on:

Sign up to be notified about upcoming events, new offerings and promotions

Join Our Mailing List

Call us to discuss which services would best fit your needs

561-893-8625